Mylan Cautions Investors Over Sell-Side Analysts' Estimates
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a surge in trading volume due to Carl Icahn's clearance to purchase up to 11.9% of Mylan stock, the company says that analysts' estimates may not reflect negative changes in the generic industry. Mylan plans to provide guidance "as soon as practically possible."